CordenPharma Forms Manufacturing Pact with Caisson BiotechBy
Caisson Biotech, LLC, a company specializing in half-life extension and drug delivery, has established a global manufacturing partnership with CordenPharma International, a contract development and manufacturing organization manufacturing active pharmaceutical ingredients and drug products through a network of cGMP facilities in Europe and the US.
Caisson has demonstrated successful technology transfer and cGMP scale-up with its corporate pharmaceutical partners using its patented heparosan-based half-life extension and drug-delivery platform, HEPtune, and will establish similar capabilities with CordenPharma in order to supply licensing partners with HEPtune drug conjugate material. As a manufacturer of the HEPtune technology, CordenPharma will bring experience and expertise in process development and manufacture of complex carbohydrates, including carbohydrate-based polymers and glyco-conjugates, which are a component of its peptides, lipids and carbohydrates technology platform offering.
Caisson is funded and managed by Emergent Technologies, Inc., headquartered in Austin, Texas.